ReviewDiscover nano2026
Bibliometric analysis of research trends on nanotechnology applications in atherosclerosis.
Review in Discover nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Atherosclerosis (AS) is a leading global health issue with limited traditional diagnostic and therapeutic precision. Nanomedicine, utilizing nanomaterials' unique properties, offers promising innovative solutions for atherosclerosis diagnosis and treatment. Studies focusing on nanotechnology and atherosclerosis were retrieved from the Web of Science Core Collection. Relevant articles were selected for inclusion in the study according to the inclusion criteria. Bibliometric analysis of the included publications was performed via VOSviewer, CiteSpace and Bibliometrix. A total of 2682 publications were included in this analysis. From 1999 to 2025, the global academic paper output exhibited a significant upward trend. China, Harvard University, and Scholar Mulder, Willem J M were the most productive country, institution, and author. The International Journal of Nanomedicine was the journal with the highest publication volume. The research on the application of nanotechnology in AS has evolved from investigating disease basic mechanisms to targeted drug delivery therapy and imaging technology, and now to the stage of multi-mechanism collaborative therapy. Future development trends focus on research into extracellular vesicles, biomimetic nanoparticles, and NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome. Relevant research may accelerate cross-integration and provide useful directions for the treatment of atherosclerotic diseases. This bibliometric analysis summarizes the current application status and research hotspots of nanotechnology in atherosclerosis and identifies future application trends. These findings provide valuable insights into the utilization and development directions of nanotechnology in atherosclerosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.